Edition:
United States

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

111.20USD
18 Oct 2017
Change (% chg)

$1.15 (+1.04%)
Prev Close
$110.05
Open
$110.41
Day's High
$111.42
Day's Low
$110.06
Volume
201,426
Avg. Vol
311,549
52-wk High
$121.44
52-wk Low
$81.13

Chart for

About

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan... (more)

Overall

Beta: 0.49
Market Cap(Mil.): $23,237.94
Shares Outstanding(Mil.): 211.16
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 162.13 16.86
EPS (TTM): -- -- --
ROI: -- 9.55 11.22
ROE: -- 14.91 15.09

Neovasc loses appeal of $112 million heart valve trade secrets award

A federal appeals court on Friday upheld an almost $112 million win for Edwards Lifesciences Corp, which accused rival medical device company Neovasc Inc of misappropriating its heart valve replacement technology.

Sep 01 2017

Edwards Lifesciences raises 2017 forecast after strong quarter

Edwards Lifesciences Corp on Wednesday provided a revised full-year earnings forecast with the new low end of the range above Wall Street estimates, and it posted higher-than-expected second-quarter profit on double-digit growth in sales of its transcatheter heart valves.

Jul 26 2017

UPDATE 2-Edwards Lifesciences raises 2017 forecast after strong quarter

July 26 Edwards Lifesciences Corp on Wednesday provided a revised full-year earnings forecast with the new low end of the range above Wall Street estimates, and it posted higher-than-expected second-quarter profit on double-digit growth in sales of its transcatheter heart valves.

Jul 26 2017

Edwards Lifesciences raises 2017 forecast after strong quarter

July 26 Edwards Lifesciences Corp on Wednesday provided a revised full-year earnings forecast with the new low end of the range above Wall Street estimates, and it posted higher-than-expected second-quarter profit on double-digit growth in sales of its transcatheter heart valve replacements.

Jul 26 2017

BRIEF-Edwards' Inspiris Resilia valve receives FDA approval

* Edwards Lifesciences Corp - Received U.S. FDA approval for its Inspiris Resilia aortic valve, first in a new class of resilient heart valves Source text for Eikon: Further company coverage:

Jul 05 2017

BRIEF-Neovasc says German Court partially found in favor of Edwards Lifesciences in its case against co

* District court in Munich has partially found in favour of Edwards Lifesciences Corporation in its case against Neovasc

Jun 16 2017

FDA approves new use for Edwards' Sapien 3 heart valve

The U.S. Food and Drug Administration on Monday approved Edwards Lifesciences Corp's Sapien 3 artificial heart valve for high-risk patients whose previously implanted heart valves are failing, a procedure designed to avoid repeat open heart surgery.

Jun 06 2017

BRIEF-Edwards Lifesciences says SAPIEN 3 valve receives FDA approval for aortic, mitral valve-in-valve procedures

* Edwards SAPIEN 3 valve receives FDA approval for aortic, mitral valve-in-valve procedures Source text for Eikon: Further company coverage:

Jun 05 2017

FDA approves new use for Edwards' Sapien 3 heart valve

The U.S. Food and Drug Administration on Monday approved Edwards Lifesciences Corp's Sapien 3 artificial heart valve for high-risk patients whose previously implanted heart valves are failing, a procedure designed to avoid repeat open heart surgery.

Jun 05 2017

UPDATE 1-FDA approves new use for Edwards' Sapien 3 heart valve

June 5 The U.S. Food and Drug Administration on Monday approved Edwards Lifesciences Corp's Sapien 3 artificial heart valve for high-risk patients whose previously implanted heart valves are failing, a procedure designed to avoid repeat open heart surgery.

Jun 05 2017

Earnings vs. Estimates